Immunoglobulin A as a Serological Marker for the (Silent) Circulation of Poliovirus in an Inactivated Poliovirus–Vaccinated Population

Poliovirus-specific immunoglobulin A (IgA) is detected after infection with wild-type virus or vaccination with live attenuated oral poliovirus (OPV) but not after vaccination with inactivated poliovirus (IPV). We examined whether the presence of IgA in serum can be used as a marker for poliovirus c...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 34; no. 8; pp. 1067 - 1075
Main Authors Herremans, Tineke, Kimman, Tjeerd G., Conyn—van Spaendonck, Marina A. E., Buisman, Annemarie, de Melker, Hester, Abbink, Fritjofna, Bijkerk, Paul, Koopmans, Marion P. G.
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 15.04.2002
University of Chicago Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Poliovirus-specific immunoglobulin A (IgA) is detected after infection with wild-type virus or vaccination with live attenuated oral poliovirus (OPV) but not after vaccination with inactivated poliovirus (IPV). We examined whether the presence of IgA in serum can be used as a marker for poliovirus circulation in IPV-vaccinated populations in The Netherlands. In seronegative persons challenged with OPV, the sensitivity of this marker was 76%-86%. Results from a serosurvey showed a high seroprevalence (63%-73%) of IgA in the population born before vaccination was introduced in The Netherlands, which reflects natural exposure. The start of the vaccination program in 1957 corresponded to a reduction in the IgA seroprevalence in both vaccinated (2.1%-4.5%) and nonvaccinated groups (8.3%-11.7%). The presence of IgA-positive persons in the population could largely be explained by the occurrence of episodes of proven poliovirus circulation. We propose to use the detection of poliovirus-specific IgA as a tool to monitor virus circulation in IPV-vaccinated and nonvaccinated populations, to aid the poliovirus eradication process.
Bibliography:ark:/67375/HXZ-SLXVJ7N1-L
istex:464F037B19E20A358215B750813BF0CF1E60527E
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1058-4838
1537-6591
DOI:10.1086/339489